Singapore Clinical Supply Facility to Receive $4.6m Investment from Catalent for Expansion
Catalent has announced it will build a new, flexible GMP space at its Singapore facility with an investment of $4.6M.
This expansion will double its ambient storage space, and quadruple cold storage capacity. It will also support global and regional customers’ growth in clinical trials activity in the Asia-Pacific region.
Established in 1998, Catalent’s Singapore site now provides full clinical supply services including project and supply chain management, comparator sourcing, clinical label printing, secondary packaging, clinical storage, import and export management, importer of record (IoR) services, and full returns and destruction management services. It has served as a key regional hub for studies in Australia, Singapore, Korea, Hong Kong and other countries in Southeast Asia.
Catalent’s President of Clinical Supply Services Wetteny Joseph commented: "Our Singapore facility is fully approved by the Health Science Authority for GMP across all its activities.
"Customer demand at the site has increased by 30% over last year, and this expansion, coupled with our recently announced opening of a facility in Japan, will allow Catalent to better support multinational customers’ growing trial’s needs, while providing more flexible solutions for local customers in the region."
With facilities in the US, the UK, Germany, Japan, and China, as well as an extended network of over 50 audited depots, Catalent’s clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements. It helps to expedite clinical trials and ensure customers are reliably supplied where and when needed worldwide.